Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB): Price and Financial Metrics


Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB): $1.34

-0.02 (-1.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TRIB Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for TRIB is -45.96 -- better than merely 0.52% of US stocks.
  • TRIB's price/sales ratio is 0.23; that's higher than the P/S ratio of merely 3.15% of US stocks.
  • TRIB's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 99.67% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Trinity Biotech Plc, a group of peers worth examining would be YI, CTK, BAK, ACFN, and VISL.
  • TRIB's SEC filings can be seen here. And to visit Trinity Biotech Plc's official web site, go to www.trinitybiotech.com.

TRIB Valuation Summary

  • TRIB's price/earnings ratio is -8.5; this is 123.29% lower than that of the median Healthcare stock.
  • TRIB's EV/EBIT ratio has moved down 502.7 over the prior 243 months.
  • Over the past 243 months, TRIB's price/earnings ratio has gone down 11.6.

Below are key valuation metrics over time for TRIB.

Stock Date P/S P/B P/E EV/EBIT
TRIB 2021-08-31 0.5 -24.6 -8.5 -500.8
TRIB 2021-08-30 0.5 -24.9 -8.6 -503.1
TRIB 2021-08-27 0.6 -25.5 -8.9 -508.6
TRIB 2021-08-26 0.5 -24.6 -8.5 -500.8
TRIB 2021-08-25 0.5 -25.2 -8.8 -506.2
TRIB 2021-08-24 0.5 -25.2 -8.8 -506.2

TRIB Growth Metrics

    The 3 year net income to common stockholders growth rate now stands at 71.27%.
  • The 4 year price growth rate now stands at -37.23%.
  • Its 2 year price growth rate is now at 48.28%.
TRIB's revenue has moved up $2,840,000 over the prior 37 months.

The table below shows TRIB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 101.98 24.671 -6.388
2019-12-31 90.435 5.875 -28.914
2018-12-31 97.035 5.978 -22.09
2017-12-31 99.14 9.37 -40.27
2016-12-31 99.611 10.556 -100.625

TRIB Stock Price Chart Interactive Chart >

Price chart for TRIB

TRIB Price/Volume Stats

Current price $1.34 52-week high $3.05
Prev. close $1.36 52-week low $0.86
Day low $1.30 Volume 24,600
Day high $1.40 Avg. volume 401,516
50-day MA $1.25 Dividend yield N/A
200-day MA $1.49 Market Cap 36.07M

Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB) Company Bio


Trinity Biotech plc develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The company was founded in 1992 and is based in Bray, Ireland.


TRIB Latest News Stream


Event/Time News Detail
Loading, please wait...

TRIB Latest Social Stream


Loading social stream, please wait...

View Full TRIB Social Stream

Latest TRIB News From Around the Web

Below are the latest news stories about Trinity Biotech Plc that investors may wish to consider to help them evaluate TRIB as an investment opportunity.

Trinity Biotech shares jump 6% premarket after WHO approves is rapid test for HIV

Dublin-based Trinity Biotech Plc shares jumped 6% premarket Monday, after the company said it has received approval from the World Health Organization for its HIV screening product, TrinScreen. The company''s Uni-Gold HIV product has served as the main confirmatory test for the detection of HIV in Africa for many years. The new product is expected to have an estimated market size of more than $150 million. "TrinScreen(TM) HIV is a rapid test providing results in less than 12 minutes from a finger stick drop of blood and the test has demonstrated excellent performance in both an independent evaluation sponsored by the WHO and in a multi-centre clinical evaluation conducted in Africa in 2020 by the Company," Trinity said in a statement. Market Pulse Stories are Rapid-fire, short news burs...

MarketWatch | February 14, 2022

Trinity Biotech wins WHO approval for HIV screening test (NASDAQ:TRIB)

Trinity Biotech (TRIB) announced on Monday that the World Health Organisation ((WHO)) approved its new HIV screening product, TrinScreen HIV.In Africa, Trinity Biotech (TRIB) has led…

Seeking Alpha | February 14, 2022

Trinity Biotech plc (NASDAQ: TRIB) Share Price Might Move Down By -82.06%

In today’s recent session, 1.08 million shares of the Trinity Biotech plc (NASDAQ:TRIB) have been traded, and its beta is 1.52. Most recently the company’s share price was $1.11, and it changed around -$0.02 or -1.78% from the last close, which brings the market valuation of the company to $24.70M. TRIB at last check was … Trinity Biotech plc (NASDAQ: TRIB) Share Price Might Move Down By -82.06% Read More »

Marketing Sentinel | February 14, 2022

Trinity Biotech shares jump 6% premarket after WHO approves its rapid test for HIV

Dublin-based Trinity Biotech Plc shares jumped 6% premarket Monday, after the company said it has received approval from the World Health Organization for its HIV screening product, TrinScreen. The company's Uni-Gold HIV product has served as the main confirmatory test for the detection of HIV in Africa for many years. The new product is expected to have an estimated market size of more than $150 million. "TrinScreen(TM) HIV is a rapid test providing results in less than 12 minutes from a finger

Yahoo | February 14, 2022

Trinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV

DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has received approval for its new HIV screening product, TrinScreen™ HIV, from the World Health Organisation (WHO). TrinScreen™ HIV Trinity Biotech’s Uni-Gold™ HIV product has been the main confirmatory test provider for the detection of the HIV virus on the African continent over many years. Trinity Biotech has developed this new product, TrinScreen™ HIV, specifically for the screening market, a market that is

Yahoo | February 14, 2022

Read More 'TRIB' Stories Here

TRIB Price Returns

1-mo N/A
3-mo 26.42%
6-mo -6.29%
1-year -55.03%
3-year -18.79%
5-year -77.67%
YTD -6.29%
2021 -62.47%
2020 268.69%
2019 -54.87%
2018 -55.10%
2017 -26.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4963 seconds.